1.Ventracor's product is approved for sale in Europe and Australia, and with high barriers for further competitors entering the market, investors should be comforted.
AFR Smart Investor Magazine 25/09/07
# VCR is 2 long years ahead of HTW.
2.We were very impressed by this device. We thought that it had a low complication rate, it's very small.
Dr Deborah Meyers, Prince Charles Hospital 12/09/07
# It is very small...small enough to be used in a child.
3.Ventracor is moving to an important inflexion point for the commercialisation of its technology. A profitable market currently exists for LVADs and there is a positive swing in events that is likely to see a wider adoption of LVADs into the far larger market of destination therapy, which is estimated to be in excess of 25,000 implants a year.
BioShares investment newsletter 22/06/07
# Thoratec, the no.1 player in the US has implanted over 11,000 devices to date. It has a market cap of over $1billion.
VCR
ventracor limited
